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Antibiotic combinations are often used for treating Pseudomonas aeruginosa infections but their efficacy toward intracellular
bacteria has not been investigated so far. We have studied combinations of representatives of the main antipseudomonal classes
(ciprofloxacin, meropenem, tobramycin, and colistin) against intracellular P. aeruginosa in a model of THP-1 monocytes in
comparison with bacteria growing in broth, using the reference strain PAO1 and two clinical isolates (resistant to ciprofloxacin
andmeropenem, respectively). Interaction between drugs was assessed by checkerboard titration (extracellular model only), by
kill curves, and by using the fractional maximal effect (FME) method, which allows studying the effects of combinations when
dose-effect relationships are not linear. For drugs used alone, simple sigmoidal functions could be fitted to all concentration-
effect relationships (extracellular and intracellular bacteria), with static concentrations close to (ciprofloxacin, colistin, and
meropenem) or slightly higher than (tobramycin) the MIC and with maximal efficacy reaching the limit of detection in broth but
only a 1 to 1.5 (colistin, meropenem, and tobramycin) to 2 to 3 (ciprofloxacin) log10 CFU decrease intracellularly. Extracellularly,
all combinations proved additive by checkerboard titration but synergistic using the FMEmethod andmore bactericidal in kill
curve assays. Intracellularly, all combinations proved additive only based on both FME and kill curve assays. Thus, although
combinations appeared to modestly improve antibiotic activity against intracellular P. aeruginosa, they do not allow eradication
of these persistent forms of infections. Combinations including ciprofloxacin were the most active (even against the ciprofloxa-
cin-resistant strain), which is probably related to the fact this drug was the most effective alone intracellularly.
Antibiotic combination is widely recognized as a useful strategynot only for increasing the chances to effectively cover the
offending organism(s) upon initiation of an empirical therapy but
also to accelerate the reduction of the inoculum at the early stage
of infection and to avoid the selection of resistance (1–4). This
may be particularly critical when dealing with infections caused by
organisms like Pseudomonas aeruginosa, which is often multiresis-
tant and causes severe diseases. Accordingly, antibiotic combina-
tions have been widely studied in vitrousing both static (5–10) and
dynamic (11–14) models. Most of these studies concluded that
there was synergy but to an extent that proved to be highly strain
dependent. While the exact mechanism of this synergy often re-
mains uncertain, a number of pharmacological reasons have been
proposed, such as the enhancement of the uptake of the compan-
ion antibiotics by colistin through its destabilizing effects on the
outer membrane (15) or the increased diffusion of entry of amin-
oglycosides through the peptidoglycan when altered by -lactams
(16).
There is, however, increasing evidence that specific lifestyles,
such as intracellular survival, may contribute to persistence of
recurrence of the infection by creating a niche refractory to anti-
biotic action. Thus, many in vitro studies with P. aeruginosa doc-
ument its ability to invade and survive within eukaryotic cells
(references 17 and 18 and references cited therein). Moreover,
intracellular reservoirs have been evidenced in vivo and appear to
be associated with the maintenance and persistence of the infec-
tion due to insufficient intracellular killing (19, 20; see reference
18 for a review). These issues are not taken into account when
assessing antibiotic combinations in vitro using classical ap-
proaches such as checkerboard titration, kill curves, or disk diffu-
sion assays.
We showed previously that the intracellular forms of P. aerugi-
nosa are poorly receptive to the action of most antibiotics, with
ciprofloxacin being the only one with a definite intracellular bac-
tericidal activity (17). Antibiotic combination may, therefore, be
an appealing strategy to increase intracellular efficacy. Past studies
made with the intracellular forms of small-colony variants of
Staphylococcus aureus (another type of organism that is poorly
susceptible to antibiotics) indeed showed that the combination of
bactericidal antibiotics can be highly synergistic (21).
In the present study, we compared the activities of combina-
tions of antibiotics, each representative of one class of well-known
antipseudomonal drugs (meropenem [carbapenems], tobramy-
cin [aminoglycosides], ciprofloxacin [fluoroquinolones], and
colistin [polymyxins]), against the extracellular and intracellular
forms of infection by P. aeruginosa using the reference strain
PAO1 and two resistant clinical isolates. We evaluated interac-
tions between drugs by use of concentration- and time-kill curves
and fractional maximal effect (FME) methods. While extracellular
synergy could easily be observed, only additivity was seen against
intracellular bacteria for all combinations studies. Our work fur-
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ther documents the difficulty of eradicating intracellular bacteria
and calls for further developments in this area to help in treating
the infections caused by P. aeruginosa.
MATERIALS AND METHODS
Bacterial strains, susceptibility testing, and extracellular kill curves.We
used P. aeruginosa strain ATCC PAO1 as a reference and two selected
clinical strains phenotypically resistant to ciprofloxacin (PA50 [bactere-
mia]) or to meropenem (PA291 [expectoration]), which were obtained
from collaborating clinical microbiology laboratories. Bacteria were
grown in Mueller-Hinton broth, and CFU counting was performed by
plating on tryptic soy agar. MICs were measured by serial 2-fold microdi-
lution according to CLSI guidelines (inoculum of approximately 106
CFU/ml and reading after 20 to 24 h of incubation) in cation-adjusted
Mueller-Hinton broth (22). Full concentration-kill curves were per-
formed as previously described (17), with a starting inoculum of 106
CFU/ml in the Muller-Hinton broth. A bactericidal effect was defined as a
decrease of the inoculum of3 log10 CFU, and the limit of detection was
a decrease of5 log10 CFU, both compared to the original inoculum.
Cells, cell culture, and intracellular infection. Human THP-1 cells
were cultivated in RPMI 1640 medium supplemented with 10% fetal calf
serum as described previously (23). Intracellular infection was performed
as previously described (17). In brief, bacteria were opsonized by 1 h of
incubation with 10% human serum in RPMI 1640 medium without fetal
calf serum. Phagocytosis was allowed for 2 h at a bacterium/cell ratio of
10:1, after which noninternalized bacteria were eliminated by incubation
for 1 h with 100 mg/liter gentamicin. After 3 washes in phosphate-buff-
ered saline (PBS) and resuspension in culture medium, the phagocytized
inoculum (determined by plating on agar and normalized with respect to
sample protein content) was typically 6.7 105 3.8 104 CFU/mg of
protein for PAO1, 6.0  105  3.2  104 CFU/mg of protein for PA50,
and 3.6 105 4.3 104 CFU/mg of protein for PA 291.
Intracellular activity of antibiotics. Antibiotics were added to the
medium of the infected cells at extracellular concentrations ranging from
0.01 to 200 mg/liter to obtain a complete description of the concentration-
response effects (17). After 24 h of incubation, cells were collected by
centrifugation, resuspended in PBS, centrifuged again to eliminate extra-
cellular bacteria, and collected in distilled water. Complete cell lysis was
achieved by sonication (10 s), and lysates were used for determination of
CFU after plating on agar of appropriate dilutions and of protein content
by Lowry’s assay using a commercially available detection kit (Bio-Rad
DCTM protein assay; Bio-Rad Laboratories, Hercules, CA). Activity was
expressed as the change from the initial inoculum after 24 h of incubation.
A Hill function (slope factor 1) was fitted to the data to calculate 4 key
pertinent pharmacodynamic parameters, namely,Emin (maximal increase
in inoculum [in log10 units] as extrapolated for an infinitely low antibiotic
concentration), Emax (maximal decrease in inoculum [in log10 units] as
extrapolated for an infinitely large antibiotic concentration), EC50 (extra-
cellular antibiotic concentration [in mg/liter] causing a reduction of the
inoculum halfway between Emin and Emax), and Cs (static concentration,
i.e., the extracellular concentration resulting in no apparent bacterial
growth).
Checkerboard titration. A two-dimensional, two-agent broth mi-
crodilution checkerboard titration method with 96-well plates was used to
study the interaction between antibiotics (24). The first antibiotic of the
combination was serially diluted along the ordinate and the second one
along the abscissa, after which a bacterial suspension (final inoculum,
0.5  106 to 1  106 CFU/ml) was added to all wells. After 20 h of
incubation at 37°C, the MIC of each antibiotic was determined as the
lowest concentration that completely inhibited the growth of the organ-
ism as detected with the naked eye. Interactions between antibiotics were
then evaluated using the FIC indices, calculated as the sum of the frac-
tional inhibitory concentrations (FICs) as follows: FIC FIC A FIC
B, where FIC A is MIC of drug A in the combination/MIC of drug A alone
and FIC B is MIC of drug B in the combination/MIC of drug B alone (25).
The combination was considered synergistic for FIC 0.5, additive for
0.5	 FIC1, indifferent for 1	 FIC	4, and antagonistic for FIC
 4, according to EUCAST definition (26).
Assessment of antibiotic combination activity. Two different meth-
ods were used to evaluate the activities of combinations against extracel-
lular or intracellular bacteria. First, antibiotics were combined at fixed
concentrations corresponding either to their respective MICs in broth or
to the maximal serum concentration (total drug) observed in patients
after administration of conventional doses of the corresponding antibi-
otic in humans (Cmax) (see references and values in reference 17). Second,
interactions between drugs within the combination were evaluated using
the fractional maximal effect (FME) approach (27, 28), as previously done
for determining interaction between antibiotics against intracellular S.
aureus (21). The concentrations of each antibiotic to be tested (Cxp) were
calculated from EC50 and Emax (defined as an FME of 1) to obtain FMEs of
0.1, 0.3, 0.5, 0.7, and 0.9, as follows: Cxp  (FME  EC50)/(1 
 FME).
Antibiotics were combined at different concentration ratios in order to
obtained an expected FME equal to 1 (i.e., concentrations of antibiotic A
[Cxp A] yielding FMEs of 0.1, 0.3, 0.5, 0.7, and 0.9, combined with con-
centrations of antibiotic B [Cxp B] yielding FMEs of 0.9, 0.7, 0.5, 0.3, and
0.1). The effect observed experimentally (Eobs) was then compared to the
effect expected for an additive effect (Exp additive) as calculated from Katz-
per’s formula (27), Exp additive [(Emax A Cxp A/EC50 A) (Emax B
Cxp B/EC50 B)]/(1 Cxp A/EC50 A Cxp B/EC50 B), which allowed us to
calculate the FME of the combination [FMEobs(A  B)] as Eobs/Exp additive.
Values of FMEobs(A B) were then plotted as a function of the concen-
tration ratios of the two drugs expected to give an FME of 1 (from 0.9:0.1
to 0.1:0.9), together with the values of the FME of each antibiotic alone
using its actual concentration. Thus, a synergistic effect will yield an ordi-
nate value larger than 1, an additive effect a value of 1, an indifferent effect
a value lower than 1 but higher than the values of the FME of the corre-
sponding antibiotics alone, and an antagonistic effect a value lower than
those of the FME of the corresponding antibiotics alone (27).
Materials. Colistin (sulfate salt; catalog no. C4461; potency, 67.50%)
was purchased from Sigma-Aldrich (St. Louis, MO). The other antibiotics
were obtained as microbiological standards from their corresponding
manufacturers (ciprofloxacin [chlorhydrate; potency, 85%] from Bayer
AG, Wuppertal, Germany, and tobramycin [potency, 100%] from SMB-
Galephar, Marche-en-Famenne, Belgium) or as the commercial product
registered in Belgium for parenteral use in humans from their respective
marketing authorization holders or resellers (gentamicin [Gentalline; po-
tency, 100%] from Schering-Plough, Brussels, Belgium, and meropenem
[Meronem, potency, 87.7%] from Astra Zeneca, Brussels, Belgium). Un-
less stated otherwise, all other reagents were of analytical grade and were
purchased from Sigma-Aldrich-Fluka. Cell culture or microbiology me-
dia were from Invitrogen (Paisley, Scotland) and Difco (Sparks, MD).
Curve fittings and statistical analyses. Curve fittings were per-
formed with GraphPad Prism (version 6.05) and statistical analyses
with GraphPad InStat 3.10, both for Windows (GraphPad Prism Soft-
ware, San Diego, CA).
RESULTS
Activity of antibiotics alone. The MICs of the selected antibiotics
for the 3 strains under study are shown in Table 1. Based on both
EUCAST and CLSI interpretive criteria, all strains were clinically
susceptible to tobramycin, while PA50 was clinically resistant to
ciprofloxacin and clinically intermediate to colistin (CLSI only)
and PA291 was clinically resistant to meropenem.
Bacteria in broth (extracellular forms) or in THP-1 cells having
phagocytized bacteria (intracellular forms) were then exposed for
24 h to a broad range of antibiotic concentrations in order to
obtain full concentration-response curves (Fig. 1) and to calculate
the pertinent pharmacodynamic parameters of antibiotic activity
(Emax, Emin, Cs, and EC50) (Table 1). As previously described for
Antibiotic Combination and Intracellular P. aeruginosa
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PAO1 (17), monophasic sigmoidal functions (with a Hill factor of
1) could be fitted to the experimental values. Against extracellular
bacteria, an apparent static effect was observed for each antibiotic
at a concentration close to its MIC, and Emax was always below the
limit of detection. Against intracellular bacteria, Emin was system-
atically lower for PA291, indicating a slower intracellular growth.
As for extracellular forms, static concentrations (Cs) against the
intracellular forms were in the range of the corresponding MIC in
broth, except for tobramycin, for which Cs values were systemat-
ically 5-fold (PA291) to 10-fold (PAO1 and PA50) higher, as pre-
viously observed for aminoglycosides against the PAO1 strain
(17). Compared to those for bacteria in broth, Emax values for
intracellular bacteria were considerably lower (less negative) for
all 4 drugs whatever the strain considered, with only a 0.5 to 2 log10
CFU decrease from the original, postphagocytosis inoculum for
colistin, tobramycin, and meropenem and about a 3 log10 CFU
decrease for ciprofloxacin. Also of interest, Emax values were sys-
tematically larger (more negative) against PA291 (except for
meropenem, to which the strain was resistant).
Checkerboard titration of antibiotic combinations. We first
examined combinations between antibiotics using the checker-
board titration assay (Table 2). The results are presented as the
lowest and highest FIC values obtained for all combinations
tested. Most combinations were additive based on the calculated
FIC (0.5	FIC1), with synergy observed only for the colis-
tin-meropenem combination against PAO1 and for the colistin-
tobramycin combination against PA50.
Combinations at fixed concentrations.Antibiotics were then
combined at two fixed concentrations, namely, (i) their respec-
tive MICs and (ii) a concentration corresponding to their hu-
man Cmax (total drug), and the decrease in CFU was evaluated
after 6 or 24 h of incubation. Against extracellular bacteria (Fig.
2), antibiotics were essentially static when tested at their MIC
in broth, whereas they were all bactericidal at 24 h at their Cmax,
except for ciprofloxacin and meropenem when tested against
the corresponding resistant strains (PA50 and PA291, respec-
tively). Combining antibiotics at their MICs allowed a 1 to 2
log10 decrease in bacterial counts at 6 h and reductions of 2 to 3
log10 for PAO1 and PA50 and of 2 log10 for PA291 at 24 h.
Combining antibiotics at their Cmax resulted in bactericidal
effects at 6 h for all antibiotic combinations tested, with the
limit of detection being reached at 6 h for PAO1 and at 24 h for
PA50 and being almost reached at 24 h for PA291. Of interest,
combinations including ciprofloxacin showed a slower effect
against the fluoroquinolone-resistant strain PA50 than other
combinations. Very contrasting results were observed against
intracellular bacteria (Fig. 3). For PAO1, combinations were
globally not more effective than the antibiotics used alone. For
PA50 and PA291, all antibiotic combinations were essentially
FIG 1 Concentration-response curves of selected antibiotics against extracel-
lular (left panels) and intracellular (THP-1 cells; right panels) P. aeruginosa
PAO1, PA50, and PA291. The graphs show the change in the number of CFU
(log10 CFU from the initial inoculum) per ml of broth (extracellular, open
symbols, dotted lines) or per mg of cell protein (intracellular, closed symbols,
solid plain lines) after 24 h of incubation at increasing extracellular concentra-
tions expressed in mg/liter (total drug). The solid horizontal line corresponds
to a bacteriostatic effect (no change from the initial inoculum), and the dotted
horizontal line shows the limit of detection (4.5 log CFU decrease). Values are
means  standard errors of the means (SEM) (2 experiments performed in
triplicate); when not visible, the error bars are smaller than the symbols. CIP,
ciprofloxacin; CST, colistin; MEM, meropenem; TOB, tobramycin.
TABLE 2 FIC indices from checkerboard titration synergy testing
Strain
Range of calculated FIC indices for drug combinationa (interpretation)
CIP-CST CIP-TOB CIP-MEM CST-TOB CST-MEM TOB-MEM
PAO1 0.56–1 (additivity) 0.75–1 (additivity) 0.63–1 (additivity) 0.63–1 (additivity) 0.26–1 (synergy/additivity) 0.56–1 (additivity)
PA50 0.56–1 (additivity) 1 (additivity) 1 (additivity) 0.26–1 (synergy/additivity) 0.56–1 (additivity) 0.63–1 (additivity)
PA291 1 (additivity) 0.53–1 (additivity) 0.63–1 (additivity) 0.75–1 (additivity) 1 (additivity) 0.75–1 (additivity)
a CIP, ciprofloxacin; CST, colistin; MEM, meropenem; TOB, tobramycin. FICs were determined by checkerboard titration; the values correspond the minimal and maximal FIC
values calculated for the different combinations of concentrations tested.
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static even when tested at an extracellular concentration corre-
sponding to their human Cmax (total drug).
Interactions in combinations by determination of FME. In
these experiments, antibiotics were combined at different con-
centration ratios calculated based on the equations of the con-
centration-response curves (Table 1) in order to cover a whole
range of combinations, starting from a proportion denoting
mainly the activity of antibiotic A (fractional maximal effect
[FME] of 0.9 for antibiotic A and of 0.1 for antibiotic B) to a
proportion corresponding to the reverse situation (FME of 0.1
for antibiotic A and of 0.9 for antibiotic B) (the actual concen-
trations tested are shown in Table 3). The experimentally ob-
served FMEs were then compared to the corresponding calcu-
lated values, and the results are shown in Fig. 4. Against
extracellular bacteria, all combinations tested appeared to be
synergistic, with bell-shaped curves indicative of a maximal
synergy when both antibiotics were combined at concentra-
tions generating an FME of 0.5. Against intracellular bacteria,
only additive effects were observed, whatever the ratio of anti-
biotic concentrations used. Figure 5 shows in a synoptic fash-
ion the gains in decreases of CFU (more negative values) ob-
served when antibiotics were combined at concentrations
allowing an FME of 0.5 to be obtained compared to the values
observed for each antibiotic when used alone at the same con-
centration (the corresponding concentrations are shown in Ta-
ble 3). For bacteria in broth, antibiotics alone caused only a 2
log10 reduction in inoculum against PAO1 or PA291 and a 3
log10 decrease against PA50 (except colistin, for which only a
2 log10 decrease was observed), while all combinations allowed
the limit of detection to be reached. For bacteria in THP-1 cells,
the intracellular inoculum was reduced by at most 1.5 log10 by
ciprofloxacin for all strains and by only 0.2 to 1 log10 by all
other antibiotics given alone. While all combinations had an
additive effect globally, the gains in decreases of CFU never
reached statistical significance over antibiotics alone except for
the colistin-tobramycin combination against PA291.
FIG 2 Influence of time on the rate and extent of killing of P. aeruginosa PAO1, PA50, and PA291 in broth by antibiotics alone or in combination used at
concentrations corresponding to their respective MIC (dotted lines) or their human Cmax (solid lines) (human Cmax values are as follows: CIP, 4.6 mg/liter; CST,
5 mg/liter; MER, 57 mg/liter; and TOB, 6 mg/liter [see reference in reference 17]). The ordinate shows the change in the number of CFU (log10 scale) per ml of
broth. The solid horizontal line corresponds to a bacteriostatic effect (no change from the initial inoculum), and the dotted horizontal line shows the limit of
detection (
4.5 log CFU decrease).Values are means SEM (2 experiments performed in triplicate); when not visible, error bars are smaller than the symbols.
CIP, ciprofloxacin; CST, colistin; MEM, meropenem; TOB, tobramycin.
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DISCUSSION
To the best of our knowledge, this study is the first one to examine
the potential of antibiotic combinations for improving antibiotic
activity against intracellular forms of P. aeruginosa. Starting from
a previously developed intracellular model of infection of THP-1
cells by the reference strain PAO1, we expanded our studies to
clinical isolates, including strains resistant to two commonly rec-
ommended antipseudomonal antibiotics. Differences in internal-
ization and intracellular growth were noticed, with PA291 being
somewhat less phagocytized and displaying slower growth than
the reference strain PAO1 or the other clinical isolate, PA50. The
reasons for these differences may be related to variations in the
expression of virulence factors, such as the type III secretion sys-
tem (29), flagellin (30), pili (31), quorum sensing (32), multidrug
efflux systems (33), or rhamnolipids (34), and will need to be
studied in details. However, they did not prevent us from per-
forming the pharmacological studies described here. Moreover,
the demonstration of the ability of these clinical isolates to survive
within the cells without killing them supports the suggested im-
portance of intracellular survival in the persistence of pseu-
domonal infection (19, 35).
Considering first the intracellular activity of antibiotics when
tested alone, we extend here our previous observation that the
relative potency of most drugs against intracellularP. aeruginosa is
directly related to their corresponding MICs as determined in
broth, even for drugs that accumulate within cells, such as cipro-
floxacin (17). This reinforces our conclusion that antibiotic accu-
mulation per se is not the only factor to consider when assessing
intracellular activity but that other parameters, such as intracellu-
lar bioavailability, need to be taken into account (see reference 36
for a recent example with fluoroquinolones and THP-1 cells in-
fected with Staphylococcus aureus or Listeria monocytogenes [typi-
cal phagolysosomal and cytosolic organisms]). In the specific case
of aminoglycosides, which accumulate to much lower levels and
FIG 3 Influence of time on the rate and extent of killing of intracellular P. aeruginosa PAO1, PA50, and PA291 by antibiotics alone or in combination used at
concentrations corresponding to their respective MIC (dotted lines) or their human Cmax (solid lines) (human Cmax values are as follows: CIP, 4.6 mg/liter; CST,
5 mg/liter; MER, 57 mg/liter; TOB, 6 mg/liter [see reference in reference 17]). The ordinate shows the change in the number of CFU (log10 scale) per mg of cell
protein. The solid horizontal line corresponds to a bacteriostatic effect (no change from the initial inoculum), and the dotted horizontal line shows the limit of
detection (
4.5 log CFU decrease). Values are means SEM (2 experiments performed in triplicate); when not visible, error bars are smaller than the symbols.
CIP, ciprofloxacin; CST, colistin; MEM, meropenem; TOB, tobramycin.
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are restricted to phagolysosomes, static concentrations are higher
than their MICs in broth, possibly due to the defeating effect of the
acidic pH of phagolysosomes on their activity (37). We also con-
firm that a fluoroquinolone such as ciprofloxacin is more effective
than the other classes of antipseudomonal drugs whatever the
resistance phenotype of the strains, indicating that the level of
intracellular efficacy of an antibiotic may also depend on its mode
of action (17). Of note, slightly higher maximal reductions in the
intracellular inoculum were achieved for PA291 for all drugs. This
is possibly related to its lower internalization, as most antibiotics
show inoculum effects.
Moving to antibiotic combinations, several methods have been
proposed in the literature to assess their use in vitro against extra-
cellular bacteria, such as checkerboard titration, time-kill curves,
disk diffusion, Etest (with crossed or closely apposed strips), or
pharmacodynamic models (24, 38), but none have been proposed
for intracellular bacteria. Concentrating first on extracellular bac-
teria, checkerboard titration is probably a most useful way for
assessing synergy in vitro, because it allows testing of a wide range
of concentrations (39). In our study, however, this method failed
to evidence any synergy between antibiotics for extracellular bac-
teria, which seems contradictory with the results obtained with the
other methods. Discordances between time-kill and checkerboard
titration methods have been previously reported (5, 25, 40, 41),
with agreement rates between the two methods as low as 50% (40).
This may be due to the methodology itself. FIC indices are highly
dependent on the applied dilution series (42), and synergy is usu-
ally considered significant only if the FIC is lower than 0.5, which
means a 4-fold reduction in the MIC measured for the combina-
tion versus each drug alone (43). Yet, more minor synergies (with
FICs between 0.5 and 1, such as those observed in the present
study) could be of clinical importance as well (44). This method
should therefore be combined with others in order to better define
interactions between drugs (45). In addition to checkerboard
titration, time-kill curves represent another reference method
whose results may better correlate with cure rates in animal mod-
els (46, 47). Its main limitation, however, is in the number of
combinations (time concentration) that can be simultaneously
tested (48). Using this approach and focusing on two concentra-
tions (MIC and human Cmax), we showed here that combinations
allow restoration of bactericidal activity against resistant strains
extracellularly, though the limit of detection was sometimes
reached more slowly than for the reference strain, as also observed
by others (49, 50). FME methodology is claimed to circumvent
this limitation by exploring broader ranges of concentrations and
taking into account the nonlinear concentration responses that
are usually observed in pharmacology (28). Under these condi-
tions, all the combinations tested proved synergistic, confirming
the widely accepted concept of using bi-or tritherapies for diffi-
cult-to-treat infections (1–4).
Moving to intracellular bacteria, the main message from our
experiments is that no synergy was observed, whatever the testing
approach used. Thus, killing curves failed to evidence any increase
in killing rates, and the FME method revealed only additive effects.
In the context of the present study, we focused on the two key and
most meaningful pharmacodynamic parameters derived from
TABLE 3 Concentrations of antibiotics (Cxp) used for the FME experiments illustrated in Fig. 4 and for the comparative activities of the most
effective combinations in Fig. 5
Antibiotic Target FME
Cxp (mg/liter)
a for strain and model:
PAO1 PA50 PA291
Extracellular Intracellular Extracellular Intracellular Extracellular Intracellular
Ciprofloxacin 0.1 0.20 0.45 26.52 35.43 1.16 0.71
0.3 0.32 0.69 45.22 51.52 1.84 1.15
0.5 0.53 1.11 78.86 80.48 3.06 1.96
0.7 1.02 2.08 157.38 148.07 5.89 3.83
0.9 3.47 6.98 549.93 485.99 20.09 13.18
Colistin 0.1 1.66 2.39 6.50 2.98 2.97 0.98
0.3 2.65 3.32 9.86 3.91 4.73 1.45
0.5 4.44 5.00 15.91 5.59 7.88 2.29
0.7 8.61 8.91 30.01 9.71 15.25 4.24
0.9 29.48 28.48 100.52 29.09 52.06 14.01
Meropenem 0.1 1.13 0.86 3.75 6.82 57.84 113.80
0.3 1.79 1.23 5.9 9.44 108.72 210.28
0.5 2.99 1.91 9.78 14.15 200.30 383.28
0.7 5.79 3.48 18.84 25.14 413.98 789.15
0.9 10.77 11.36 64.12 80.12 1482.39 2815.20
Tobramycin 0.1 0.39 11.31 1.75 12.42 1.15 3.50
0.3 0.61 15.34 2.77 16.83 1.82 5.20
0.5 1.00 22.61 4.6 24.78 3.03 8.26
0.7 1.91 39.56 8.89 43.31 5.85 15.40
0.9 6.50 124.32 30.30 135.96 19.97 51.10
a Concentration of each individual antibiotic in the combination calculated to reach an FME ranging from 0.1 to 0.9, using the EC50s from the sigmoid equation of the
concentration-effect experiments presented in Fig. 1 (see values in Table 1) and based on the following equation: Cxp (FME EC50)/(1
 FME). Concentration values in bold
are those used in Fig. 5, corresponding to a FME of 0.5 for each drug in the combination.
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FIG4 FME plots of antibiotics against extracellular (open symbols, dashed lines) and intracellular (closed symbols, solid lines)P. aeruginosa strains. In each graph, the
abscissa shows the FMEs value calculated for antibiotics A and B based on concentration effects shown in Fig. 1 (see Table 3 for the corresponding concentra-
tions), and the ordinate shows the value of the FMEobs for each antibiotic alone or for the combination. FMEobs values for the combination that are1 denote
a synergistic effect, values equal to 1 an additive effect, values 	1 but higher an indifferent effect, and values 	1 and lower than FMEobs for each individual
antibiotic in the combination an antagonistic effect.
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concentration effect-kill curves, namely, Emax and EC50 (27, 28),
to select concentrations to be tested. This method has been applied
successfully in other models of intracellular infection to demon-
strate synergy (21), which means that the negative results observed
here need to be taken at face value. Also, the fact that our FME
experiments parallel the kill curve experiments for the intracellu-
lar model lends more credence to our results. We now have to
understand why synergy is lost intracellularly, which may be re-
lated, among many possibilities, to modulations of bacterial me-
tabolism in the intracellular milieu (making them less susceptible
to antibiotic action) or to intracellular sequestration of the bulk of
the antibiotics in distinct subcellular compartments (reducing
their effective concentration at the site of infection). This con-
trasts with our previous observations using the same approach
with intracellular small-colony variants of S. aureus, where we
showed that combining highly bactericidal antibiotics (oritavan-
cin, moxifloxacin, or rifampin) can provide considerable gains in
reduction of the intracellular bacterial load (21). Elucidating the
reasons why intracellular P. aeruginosa is acted upon poorly by
antibiotics, such as exploring how the cellular environment may
affect its responsiveness, could help in defining novel strategies to
better act upon these persistent forms of infection.
Although leading to coherent observations, this study suffers
from limitations inherent to the model. First, we could not include
strains resistant to aminoglycosides, because we did not find any
efficient alternative to a short incubation with gentamicin to elim-
inate extracellular bacteria. Colistin-resistant strains could not be
studied either, since all strains we had access to were also resistant
to aminoglycosides. Second, the number of strains that could be
analyzed was small due to the complexity of experiments dealing
with combinations of multiple concentrations against intracellu-
lar bacteria. Taking these caveats into account, we can neverthe-
less draw some pharmacologically and possibly also clinically
meaningful conclusions. In a nutshell, we found that antibiotic
combinations provided no more than an additive effect against
intracellular P. aeruginosa, even when combining drugs at their
human Cmax, which may represent the maximal exposure in hu-
mans. This may explain why eradication of P. aeruginosa seems
such a difficult-to-achieve goal, as intracellular bacteria may rep-
resent a protected storage site from which unaffected organisms
can be liberated even during or after conventional antibiotic treat-
ments.
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